{"protocolSection": {"identificationModule": {"nctId": "NCT00243165", "orgStudyIdInfo": {"id": "LifemelCTIL"}, "organization": {"fullName": "Rambam Health Care Campus", "class": "OTHER"}, "briefTitle": "Lifemel Honey to Reduce Leucopenia During Chemotherapy", "officialTitle": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"}, "statusModule": {"statusVerifiedDate": "2005-10", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-11"}, "studyFirstSubmitDate": "2005-10-20", "studyFirstSubmitQcDate": "2005-10-20", "studyFirstPostDateStruct": {"date": "2005-10-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-12-04", "lastUpdatePostDateStruct": {"date": "2009-12-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "Rambam Health Care Campus", "class": "OTHER"}, "collaborators": [{"name": "Zuf Globus Laboratories Ltd.", "class": "OTHER"}]}, "descriptionModule": {"briefSummary": "This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity."}, "conditionsModule": {"conditions": ["Breast Cancer"], "keywords": ["breast cancer", "honey", "myelosuppression", "chemotherapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 60, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "BEHAVIORAL", "name": "Lifemel honey intake every day"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Prevention of myelotoxicity-every week during chemotherapy."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* breast cancer patient treated with adjuvant chemotherapy\n* PS = 2 or less\n\nExclusion Criteria:\n\n* none", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Georgeta Fried, MD", "role": "CONTACT", "phone": "972-4-8543018", "email": "g_fried@rambam.health.gov.il"}], "overallOfficials": [{"name": "Georgeta Fried, MD", "affiliation": "Rambam Health Care Campus", "role": "PRINCIPAL_INVESTIGATOR"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}}, "hasResults": false}
